Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 4:42 AM ET

Pharmaceuticals

Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd. engages in the discovery and development of macro-cycle drugs. The company offers MacroFinder molecules, which penetrate into the cells to hit intracellular protein-protein interactions (PPI); and PEMfinder molecules that are used to address extracellular large surface PPI-targets. Its macro-cycles drugs target various therapeutic areas, such as hematopoietic stem cell transplantations, leukemia, pseudomonas infections, cystic fibrosis, alpha-1 antitrypsin deficiency, and chronic obstructive pulmonary diseases. The company was founded in 1996 and is headquartered in Allschwil, Switzerland.

Hegenheimermattweg 125

Allschwil,  4123

Switzerland

Founded in 1996

Phone:

41 61 567 16 00

Fax:

41 61 567 16 01

Key Executives for Polyphor Ltd

Chief Executive Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Director
Chief Financial Officer and Head of Coporate Development
Head of Technology Platforms
Compensation as of Fiscal Year 2015.

Polyphor Ltd Key Developments

Polyphor Ltd Announces Extension of its R&D Collaboration with Novartis

Polyphor Ltd. announced the extension of its R&D collaboration with Novartis focused on Polyphor's PEM (Protein Epitope Mimetic) drug discovery technology. Under the terms of the extension the parties will work together towards the nomination of a clinical PEM macrocycle drug candidate. Polyphor will receive funding for its research and development activities related to the collaboration project and will be eligible for preclinical and clinical development milestones and royalties on the commercial sales of approved products. Novartis is responsible for clinical development and commercialization.

Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015

Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates

Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.

Similar Private Companies By Industry

Company Name Region
ACIC Europe Limited Europe
Novartis International AG Europe
Qenax AG Europe
Speciality European Pharma International AG Europe
Omnimedica AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polyphor Ltd, please visit www.polyphor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.